Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2 manufacturers
|
| | Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2 Basic information |
| Product Name: | Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2 | | Synonyms: | GLP-GLN-PHE-(NME)PHE-SAR-LEU-MET-NH2;[GLP5,(ME)PHE8,SAR9] SUBSTANCE P (5-11);(PYR5,N-ME-PHE8,SAR9)-SUBSTANCE P (5-11);SUBSTANCE P [PGLU5, N-ME-PHE8, SAR9]-FRAGMENT 5-11;PGLU-GLN-PHE-N-METHYL-PHE-SAR-LEU-MET-NH2;PGLU5,MEPHE8,SAR9-SUBSTANCE P FRAGMENT*5 -11;SUBSTANCE P (PGLU5,MEPHE8,SAR9)-*FRAGMEN T 5-11;[pglu5, n-me-phe8, sar9]-substance p fragment 5-11 | | CAS: | 77128-69-9 | | MF: | C43H61N9O9S | | MW: | 880.07 | | EINECS: | | | Product Categories: | | | Mol File: | 77128-69-9.mol |  |
| | Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2 Chemical Properties |
| Boiling point | 1291.2±65.0 °C(Predicted) | | density | 1.257±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | form | Solid | | pka | 13.13±0.20(Predicted) | | color | White to off-white | | Sequence | pGlu-Gln-Phe-N-Methyl-Phe-Sar-Leu-Met-NH2 |
| | Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2 Usage And Synthesis |
| Uses | [Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats[1][2][3]. | | in vivo | [Glp5,(Me)Phe8,Sar9] Substance P (5-11) (2 μg/side; inject into the ventral tegmental area; single) exhibits selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain[1].
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (0.5, 1.5, 3 μg/side; inject into the ventral tegmental area; single) increases motor activity and induces recovery of addictive agent-seeking behavior in rats[2]. | Animal Model: | Male Sprague-Dawley rats (300-350 g)[1]. | | Dosage: | 2 μg/side | | Administration: | Inject into the ventral tegmental area; single | | Result: | Selectively activated mesolimbic and mesocortical dopamine metabolism. |
| Animal Model: | Male Wistar rats (300-350 g)[2]. | | Dosage: | 0.5, 1.5, 3 μg/side | | Administration: | Inject into the ventral tegmental area; single | | Result: | Significantly increased locomotor activity when at 3 μg/side. |
| | References | [1] Elliott PJ, et al. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. Brain Res. 1986 Jan 15;363(1):145-7. DOI:10.1016/0006-8993(86)90667-0
[2] Eison AS, et al. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. Science. 1982 Jan 8;215(4529):188-90. DOI:10.1126/science.6171884
[3] Placenza FM, et al. Infusion of the substance P analogue, DiMe-C7, into the ventral tegmental area induces reinstatement of cocaine-seeking behaviour in rats. Psychopharmacology (Berl). 2004 Dec;177(1-2):111-20. DOI:10.1007/s00213-004-1912-9 |
| | Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2 Preparation Products And Raw materials |
|